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Original ArticleThe DERIVO Embolization Device in the Treatment of Intracranial Aneurysms: Short- and
Midterm ResultsErol Akgul1, Hasan Bilen Onan1, Suha Akpinar2, Huseyin Tugsan Balli1, Erol Huseyin Aksungur1-OBJECTIVE: The DERIVO embolization device (DED) is a
new nitinol flow diverter stent manufactured for the
treatment of intracranial aneurysms. In this study, we
evaluated the safety and efficacy of the DED in the treat-
ment of intracranial aneurysms and present the short- and
midterm results.
-METHODS: We treated 34 aneurysms using 26 devices in
24 patients with wide-necked, mostly medium-sized, and
fusiform aneurysms. Fourteen of the patients included in
the study were women and the other 10 were men. Head-
ache was the most frequent symptom. Although 31 (91.2%)
aneurysms were in the anterior circulation, 3 (8.8%) were
in the posterior. Intracranial stent medication was
accomplished in all patients. All patients were evaluated 1
day later for any ischemic lesion with diffusion-weighted
imaging. The first and second follow-up angiograms were
planned to be performed after 3 and 9 months.
-RESULTS: In all patients, the treatment was successful.
No hemorrhagic complication was seen on computed to-
mography scan performed immediately after the procedure.
All patients were discharged without any neurologic
deficit. Although 20 (71.4%) of 28 aneurysms in 20 patients
were totally closed on the 3-month follow-up angiogram, 14
(77.8%) of 18 aneurysms in 9 patients were totally closed on
the 9-month follow-up. General morbidity was 8.4%, and
mortality was 4.3%.
-CONCLUSIONS: The DED seems effective and safe in the
treatment of different kinds of intracranial aneurysms.Key words
- Cerebral aneurysm
- DERIVO endovascular device
- Endovascular treatment
- Flow diverter
- Stent
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WORLD NEUROSURGERY 95: 229-240, NOVEMBER 2016INTRODUCTIONndovascular treatment of any kind of cerebral aneurysmwith
or without balloon- or stent-assisted coiling is a safe andEeffectivemethod.1-6With larger and fusiform aneurysms, the
recanalization rates are more than 30% and have been reported as
being 50%e60% in some studies.2,7 Endovascular treatment limi-
tations and the high rate of recanalization in those aneurysms have
forced researchers to investigate new devices to decrease the
recanalization rate and be able to treat any kind of aneurysms.1,5,8-10
For these reasons, ﬂow diverter (FD) stents, such as Pipeline (Cov-
idien AG, Paris, France), Silk (Balt Extrusion, Montmorency,
France), Surpass (Stryker Corp., Kalamazoo, Michigan, USA), and
FRED (Microvention Terumo, Tustin, California, USA), have been
widely used for the last 7e8 years. All have provided major advance
in the treatment of wide-necked, fusiform, giant, and also ruptured
or nonruptured small or blister-like intracranial aneurysms, which
are difﬁcult or impossible to treat.2,4-6,8,9,11-23
Among the various FD stents, the DERIVO embolization device
(DED) is a new nitinol FD stent (Acandis GmbH & Co. KG,
Pforzheim, Germany). In this study, we evaluate the safety and
efﬁcacy of the DED in the treatment of intracranial aneurysms and
present the short- and midterm results.METHODS
Patients
The patients treated with the DED were retrospectively evaluated
in 2 centers. Written informed consent was obtained from all
patients. We treated 34 aneurysms using 26 devices in 24 patients
with wide-necked, mostly medium-sized, and fusiform aneu-
rysms. Of the aneurysms, 4 (11.8%) were giant, and 7 (20.6%)
were big. Only 3 (8.8%) were fusiform. Fourteen of the patients
included in the study were women, and the other 10 were men.To whom correspondence should be addressed: Erol Akgul, M.D.
[E-mail: akgulerol@gmail.com]
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treated in the same session with other endovascular methods than
the DED, were excluded from the study. Headache was the most
frequent symptom. Although 31 (91.2%) aneurysms were in the
anterior circulation, 3 (8.8%) were in the posterior. Tables 1 and 2
show the patients’ data and the aneurysm characteristics in
chronologic order of treatment performed.
Only one of the aneurysms had ruptured. This patient had 2
aneurysms. One was ophthalmic, and the other, ruptured andTable 1. Patient Data and Aneurysm Characteristics
Characteristic Value
Number of patients 24
Age range (years) 30e77
Mean 50.1
Sex
Male 10 (41.7)
Female 14 (58.3)
Symptoms
Headache 16 (66.6)
SAH 1 (4.2)
Visual disturbances 1 (4.2)
Difficulty in swallowing and speech 1 (4.2)
Incidental 1 (4.2)
Recanalization during follow-up 4 (16.6)
Total aneurysms treated 34
Aneurysm size
Small (3 mm) 4 (11.8)
Medium (4e10 mm) 19 (55.8)
Large (11e24 mm) 7 (20.6)
Giant (25 mm) 4 (11.8)
Aneurysm type
Saccular 31 (91.2)
Fusiform 3 (8.8)
Aneurysm location
Anterior circulation 31 (91.2)
ICA terminal 4
Anterior choroidal 3
Posterior communicating 5
Ophthalmic/clinoid 15
Cavernous 4
Posterior circulation 3 (8.8)
Vertebrobasilar 3
Values are number of participants, mean (%), or as otherwise indicated.
SAH, subarachnoid hemorrhage; ICA, internal carotid artery.
230 www.SCIENCEDIRECT.com WORLD NEUlarger one, was an internal carotid artery (ICA) terminal segment
aneurysm. The aneurysms were coiled in the acute stage and
treated with a DED 3 months later (Tables 2 and 3, patient 9).
Three aneurysms in 3 patients had been treated 8 years, 3 years,
and 4 months previously because of rupture, respectively. Those
aneurysms were recanalized and treated with DEDs (Tables 2
and 3, patients 14, 15, and 23, respectively). One patient was
treated for a growing aneurysm, which had been treated with
wrapping 5 years previously (Tables 2 and 3, patient 16).
DED
The DED is a FD consisting of 24 wires that are looped at the
distal end and so result in a braid of 48 wires. All wires are
nitinol with a radiopaque platinum core. A 27 microcatheter is
required for the delivery of the device. The DED is available in
lengths between 15 and 50 mm and diameters between 3.5 and 6
mm. It has closed distal ends and a ﬂaring of 25 to the outside
at both ends for secure wall apposition immediately after the
initial distal opening. The DED has a braiding angle of 75 and a
porosity of 62%e65%. The 4.0- and 4.5-mm DEDs provide a
pore density of 15e19 pores per square millimeter and a pore
size of 0.042e0.053 mm2 at the nominal diameter. The device
can be safely recaptured before the point of no return and
repositioned if an adjustment and superior placement is needed.
An approximately 50-nm thin layer of titanium oxide and tita-
nium oxynitride characterizes the surface of the device. The
deep-blue color (blueXide [Acandis GmbH & Co. KG]) is real-
ized by means of a combined electropolishing and annealing
process. This unique surface treatment is responsible for the
extreme smoothness of the wires and the outstanding corrosion
resistance of the device. The ﬁrst generation of the DED had 2
braided nitinol wires with platinum cores, arranged in a spiral
conﬁguration, and 3 platinum-iridium markers at the proximal
and distal ends of the device. Visibility was sufﬁcient, but in
some cases it was not easy to see the device properly over
compact bones. With the new version of the DED, all nitinol
wires feature an opaque platinum core, in addition to the
radiograph markers on both ends. The radiopaque wires make
the contour of the device clearly visible (Figure 1).24,25 The new
version of the DED was used in only 4 patients (Table 3,
patients 22e24).
Endovascular Technique
After general anesthesia was administered, access was gained to the
ICA or the vertebral artery using long introducers (Neuron MAX 6F
[Penumbra Inc., Alameda,California, USA]) anddistal access guiding
catheters (DAC [Stryker], Fargo [Balt], and Navien [Covidien AG])
(Tables 2 and 3). Before insertion of the DED, if coiling was planned,
embolization was performed via an Excelsior SL-10 Microcatheter
(Stryker), with or without using an aneurysm neck-remodeling
balloon. The jailing technique was only used in 1 patient for coiling
(Tables 2 and 3, patient 18). A Headway 27 (Microvention Terumo) or
Rebar 27 (Covidien AG) microcatheter was inserted in the parent
artery using a Terumo 0.016 (Terumo Medical Corp., Tokyo, Japan)
or Synchro 0.014 (Stryker) microguidewire, the distal end of the
microcatheter passing the aneurysm neck by approximately 2 or 3
cm. Then a suitable DED was deployed to cover the neck of the
aneurysm. Correct expansion of the stent was detected underROSURGERY, http://dx.doi.org/10.1016/j.wneu.2016.07.101
Table 2. Patient Data and Aneurysm Characteristics with Diameters
Patient
Number Age/Sex Clinical History and Presentation
Number of
Aneurysms Location (type)
Maximum
Diameter/Neck (mm)
1 55/M Headache 1 R ICA terminus (F) 25
2 46/F Headache 1 R PCom (S) 9/5
3 55/F Headache 1 L PCom (S) 26/7
4 55/F Headache 1 R PCom (S) 27/6
5 58/M Headache 3 L cavernous (S) 3/3
L cavernous (S) 3/2
L cavernous (S) 1.5/1
6 51/F Headache 3 R ophthalmic (S) 14/5
L ophthalmic (S) 7/4
L ophthalmic (S) 4/3
7 58/F Headache 3 R ICA terminus 5/3
R ICA terminus 3/2
R Ant. chroidal 3/2
8 32/M Right ICA occlusion caused by trauma 3 years
previously
1 L vertebrobasilar junction (F) 8
9 56/F Ophthalmic and terminal segment aneurysms
were coiled because of SAH
2 L ICA terminus (S) 7/3
L ophthalmic (S) 6/3
10 49/F Headache 2 R AChor (S) 3/3
R ophthalmic (S) 3/3
11 77/F Headache 1 L ophthalmic (S) 14/8
12 62/F Headache 1 L cavernous (S) 29/7
13 52/M Headache 1 L ophthalmic (S) 10/5
14 42/M Recanalized vertebrobasilar junctional aneurysm
coiled 8 years previously because of SAH
1 Vertebrobasilar junction (S) 4/3
15 40/M Recanalized aneurysm coiled 3 years previously
because of SAH
1 L PCom (S) 5/4
16 57/F Residual aneurysm surgically treated with
wrapping 5 years previously
1 R PCom (S) 5/6
17 35/F Severe headache 1 L AChor (S) 6/3
18 40/F Headache and visual disturbances 1 R ophthalmic (S) 22/7
19 41/M Headache 1 L ophthalmic (S) 5/3
20 56/F Headache 1 L ophthalmic (S) 11/5
21 61/M Difficulty in swallowing and speaking 1 R vertebrobasilar (F) 24
22 60/F Headache 3 R Ophthalmic (S) 11/5
R Ophthalmic (S) 4/3
R Ophthalmic (S) 2/2
23 30/M Recanalized aneurysm coiled 4 months previously
because of SAH
1 L ophthalmic (S) 4/4
24 65/F Headache 1 L ophthalmic (S) 11/5
M, male; R, right; ICA, internal carotid artery; (F), fusiform; F, female; PCom, posterior communicating artery; (S), saccular; L, left; Ant., anterior; SAH, subarachnoid hemorrhage; AChor, anterior
choroidal.
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Table 3. Procedural and Follow-up Data
Patient
Number Location (type)
DERIVO
Sizes (mm) Coil
Complications
DWI
DSA
(3 months)
DSA
(9 months)
Follow-up (months)/
Comments<24 Hours 1e30 Days >30 Days
1 R ICA terminus (F) 4.5  25 e e e Exitus in
sixth month
e Incomp. 6/exitus because of aneurysmal
hemorrhage/mRS: 6
2 R PCom (S) 4  20 þ e e e e Comp. Comp. 12/mRS: 0
3 L PCom (S) 4  20 þ e Stent thrombosis
at third day
e Comp. Comp. 12/stent occlusion was treated
with thrombolysis and
mechanical thrombectomy/
clopidogrel resistant/mRS: 1
4 R PCom (S) 4.5  20 þ Stent fish-
mouthing
e e e Comp. Comp. 12/second DERIVO was because
of fish-mouthing/mRS: 0
5 L cavernous (S) 5.5  30 e Thromboembolism e e þ Incomp. Incomp. 11/right hemiplegia right after
procedure/no vessel occlusion
on DSA/IV tirofiban/ipsilateral
frontoparietal ischemia on DWI/
mRS: 0
L cavernous (S) e e e Incomp. Incomp.
L cavernous (S) e e e Incomp. Incomp.
6 R ophthalmic (S) 4  20 þ e e e e Comp. Comp. 10/aneurysms and bilateral
fibromuscular dysplasia at ICA
were treated in 2 sessions/
mRS: 0
L ophthalmic (S) 4  25 þ e e e e Comp. Comp.
L ophthalmic (S) e Comp. Comp.
7 R ICA terminus 4  20 þ e e e e Comp. Comp. 9/mRS: 0
R ICA terminus e Incomp. Comp.
R Ant. choroidal e Incomp. Incomp.
8 L vertebrobasilar
junction (F)
4  20 e e e e e Comp. Comp. 9/mRS: 0
9 L ICA terminus (S) 4  20 þ e e e e Comp. Comp. 9/mRS: 0
L ophthalmic (S) þ Comp. Comp.
10 R AChor (S) 4  25 e e e e NA Comp. Comp. 9/DWI could not be performed
because of cardiac pacemaker/
mRS: 0
R ophthalmic (S) e Comp. Comp.
11 L ophthalmic (S) 5  30 þ e e e e Incomp. 9/mRS: 0
12 L cavernous (S) 4.5  30 þ e e e e Comp. 9/50% stenosis in distal part of
DERIVO/mRS: 0
13 L ophthalmic (S) 4.5  20 þ e e e þ Comp. 9/ipsilateral 2 small ischemic
lesions on DWI/mRS: 0
14 Vertebrobasilar
junction (S)
4.5  25 e e e e þ Comp. Comp. 9/3 small mesencephalic,
cerebellar, and hypocampal
ischemic lesions on DWI/mRS: 0
15 L PCom (S) 4  20 e e e e þ Comp. 7/ipsilateral one small frontal
cortical ischemic lesion on DWI/
mRS: 0
16 R PCom (S) 4.5  25 e e e e e Incomp. 7/mRS: 0
17 L AChor (S) 4  20 þ e e e e Comp. 6/mRS: 0
18 R ophthalmic (S) 4  20 þ e e e e Comp. 6/coiling was performed with a
jailed microcatheter/mRS: 0
19 L ophthalmic (S) 4.5  20 þ e e e e Comp. 6/mRS: 0
Continues
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Table 3. Continued
Patient
Number Location (type)
DERIVO
Sizes (mm) Coil
Complications
DWI
DSA
(3 months)
DSA
(9 months)
Follow-up (months)/
Comments<24 Hours 1e30 Days >30 Days
20 L ophthalmic (S) 4  20 þ þ e e þ Comp. 3/premature coil detachment,
unrelated to DERIVO
deployment/ipsilateral many
small frontoparietal ischemic
lesions on DWI/mRS: 0
21 R vertebrobasilar
(F)
6  50,*
6  40,*
6  30
e e e e e e 2
22 R ophthalmic (S) 4  20* þ þ e e e e 2/mRS: 0
R ophthalmic (S) e e
R ophthalmic (S) e e
23 L ophthalmic (S) 4.5  20* e e e e e 2/mRS: 0
24 L ophthalmic (S) 3.5  20* e e e e e 1/mRS: 0
R, right; ICA, internal carotid artery; (F), fusiform; Incomp., incomplete; mRS, Modified Rankin Scale; PCom, posterior communicating artery; (S), saccular; Comp., complete; L, left; IV,
intravenous; DWI, diffusion-weighted imaging; Ant., anterior; AChor, anterior choroidal; DSA, Digital Subtraction Angiography; NA, not applicable.
*New version of DERIVO.
Figure 1. DERIVO embolization device (new version).
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[Covidien AG], Scepter C [Microvention Terumo], Transform
[Stryker], and Eclipse [Balt]) was applied to provide proper
apposition of the stent to the vessel wall.
Medication
Intracranial stent medication was accomplished. Seven to 10 days
before the treatment, double antiplatelet medicines were
administered: 100 mg of acetylsalicylic acid (Aspirin [Bayer
Healthcare AG, Nordrhein-Westfalen, Germany]) and 75 mg of
clopidogrel (Plavix [Bristol-Myers Squibb/Sanoﬁ Pharmaceuticals,
New York, New York, USA]) a day. We evaluated the sensitivity of
clopidogrel and acetylsalicylic acid with VerifyNow (Accumetrics
Inc., San Diego, California, USA) 1 or 2 days before the treatment.
According to the sensitivity of the antiplatelets, if acetylsalicylic
acid sensitivity was under the threshold, the dose was increased
to 300 mg a day, and if clopidogrel sensitivity was under 30%,
clopidogrel was replaced with ticlopidine (Ticlocard [Koçak
Farma, Istanbul, Turkey]). Acetylsalicylic acid was ordered to
continue indeﬁnitely, and clopidogrel or ticlopidine was dis-
continued after 6 months. If there was a problem with acetylsa-
licylic acid sensitivity or gastrointestinal intolerance,
acetylsalicylic acid was discontinued, and lifetime clopidogrel was
ordered (Table 3).
After femoral artery access, 5000 IU heparin was administered
intravenously, targeting 2 or 3 times the baseline value, and the
serum-activated coagulation time was checked. During the pro-
cedure, 1000 IU or more of heparin was administered per hour to
maintain the serum-activated coagulation time level stable. After
the procedure, 750e1000 IU/h heparin was infused for 24 hours.
Low-molecular weight heparin (20.4e0.6 mL) was administered
subcutaneously for 1e5 days after cessation of intravenous
heparin.WORLD NEUROSURGERY 95: 229-240, NOVEMBER 2016Follow-Up
After the procedure, Dyna CT (Artis zee, Munich, Germany) was
performed to detect any hemorrhagic complication that might
have occurred during the procedure. All patients were evaluated 1
day later for any new symptomatic or asymptomatic ischemic
lesions with diffusion-weighted imaging (DWI). The ﬁrst and
second follow-up angiograms were planned to be performed after
3 and 9 months.RESULTS
In all patients, the treatment was successful. In one patient, 3
DEDs were implanted to treat a long fusiform aneurysm of thewww.WORLDNEUROSURGERY.org 233
Figure 2. Patient 4: Axial T2-weighted magnetic
resonance imaging (A), angiograms in Town’s (B)
and lateral (C) projections, and 3-dimensional
angiography image (D) show a giant, partially
thrombosed right posterior communicating artery
aneurysm. The posterior communicating artery
comes from the inferior part of the aneurysm neck.
One to 2 minutes after deployment of the DERIVO
embolization device (E), the proximal part of the
stent (first version) changed into fish-mouth
formation (F and G). A remodeling balloon was
applied but neither proper apposition nor a return to
its original shape could not be obtained. Another
DERIVO embolization device was inserted, and
sufficient apposition was obtained (H). Stasis of the
contrast medium is seen in the angiogram (I). The 3-month follow-up angiogram shows both total closure of the aneurysm and minimal intimal
hyperplasia adjacent to the overlapped part of the stents (J). In the 9-month follow-up angiogram (K), the hyperplasia has disappeared.
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DEDs were used for 1 aneurysm because of the stent’s ﬁsh-mouth
formation (Figure 2 and Tables 2 and 3, patient 4). In another
patient with 2 aneurysms in each side, 2 DEDs were implanted
(Tables 2 and 3, patient 6). A remodeling balloon was applied to
provide proper apposition of the DED to the vessel wall in 9
(37.5%) patients (Tables 3 and 4).
No hemorrhagic complication was seen on computed
tomography scan performed immediately after the procedure. In
one patient, right hemiparesis occurred directly after the proced-
ure. A computed tomography scan showed no hemorrhage, and
an angiogram was performed. No thromboembolic occlusion was
seen. The patient was treated with intravenous tiroﬁban (Aggrastat
[Merck & Co., Inc., Whitehouse Station, New Jersey, USA]), and a
DWI performed 1 day later showed ipsilateral small frontoparietal
cortical cerebral infarction. The patient was discharged without
any neurologic deﬁcit (Tables 2 and 3, patient 5).
A patient with a left posterior communicating artery aneurysm
treated with coil and DED was admitted 3 days later because of aTable 4. Procedural Parameters
Parameter Value
Guide catheter (n ¼ 25)
Navien 5F (Covidien AG) 15 (60.0)
Navien 6F (Covidien AG) 1 (4.0)
Fargo Max (Balt) 2 (8.0)
Fargo (Balt) 1 (4.0)
Fargo Mini (Balt) 1 (4.0)
DAC 5F (Stryker) 4 (16.0)
DAC 4.3 (Stryker) 1 (4.0)
Delivery microcatheter (n ¼ 25)
Headway 27 (Microvention Terumo) 21 (84.0)
Rebar 27 (Covidien AG) 4 (16.0)
Cases requiring balloon dilation 9 (37.5)
Treated aneurysm
With coiling 16 (47.1)
Without coiling 18 (52.9)
Total DERIVO devices used 26
Number of DERIVO devices per cases 1.1
1 23
2 2
3 1
Number of DERIVO devices per aneurysm 0.8
Antiplatelet treatment
alicylic acid/clopidogrel 20 (83.3)
Salicylic acid/ticlopidine 4 (16.7)
Values are number (%) or as otherwise indicated.
WORLD NEUROSURGERY 95: 229-240, NOVEMBER 2016right-side hemiplegia and aphasia. The patient had stent occlu-
sion caused by thrombosis and was treated with thrombectomy
and intra-arterial tissue plasminogen activator. The patient was
discharged with mild paresis and dysarthria (Tables 2 and 3,
patient 3). This patient was not sensitive to clopidogrel, and
clopidogrel was replaced with ticlopidine, to which the patient
was sensitive.
Another patient with a giant and fusiform aneurysm of the
terminal segment of the right ICA had been treated with only a
DED without coiling. The stagnation of contrast medium was
seen immediately after the device implantation. This was the ﬁrst
giant aneurysm that we treated with a FD without coiling.
This patient suffered twice from severe headache, 15 days and
2 months later. Computed tomography scan and magnetic reso-
nance imaging were performed, and severe perianeurysmal edema
was seen. The patient was hospitalized, treated with dexameth-
asone, and discharged without any neurologic problems. The
3-month follow-up angiogram showed partial ﬁlling of the
aneurysm and moderate (less than 50%) intimal hyperplasia
inside the proximal part of the device. The patient was admitted
with loss of consciousness in the sixth month, and it was
discovered that the aneurysm had ruptured. The patient died
15 days later (Tables 2 and 3, patient 1).
In 5 (21.7%) of 23 patients, there were 1 or more small
asymptomatic ischemic lesions on DWI (Tables 3 and 5). DWI
could not be performed on one patient because of her cardiac
pacemaker (Tables 2 and 3, patient 10).
Although 20 (71.4%) of 28 aneurysms in 20 patients were totally
closed on the 3-month follow-up angiogram, 14 (77.8%) of 18
aneurysms in 9 patients were totally closed on the 9-month follow-
up (Figure 3 and Table 3). Any additional beneﬁt of coiling the
aneurysm before DED deployment was not evaluated statistically
because of the small number of aneurysms treated.
In only 1 of the 20 patients (5%), asymptomatic intimal hyper-
plasia causing stenosis equal to approximately 50% was detected
on the 3-month follow-up angiography (Table 3, patient 12).
General morbidity was 8.4%, and mortality was 4.3%. Other
statistical data are shown in Table 5.DISCUSSION
The use of FDs in the treatment of anatomically complex aneu-
rysms, which are difﬁcult to treat with routine endovascular or
microsurgical techniques, has been widely accepted in recent
years. Many studies have emerged recently showing that FDs have
been a very safe and effective endovascular treatment method for
nonruptured, wide-necked, big or giant aneurysms and for fusi-
form aneurysms. These studies have shown that FDs have been
suitable and efﬁcacious in the treatment of small- and medium-
sized aneurysms located in anterior or posterior circulation, and
proximal or distal to the Willis polygon as well. Additionally,
ruptured blistered aneurysms, in which rebleeding and mortality
rates have been very high with conventional microsurgical and
endovascular treatment techniques, have been more and more
frequently treated with FDs.14,18,21,26 The FD technique relies on
the concept of endoluminal reconstruction of the parent artery
and the exclusion of the aneurysm from the circulation. The stasis
of blood ﬂow in the aneurysm leads to an inﬂammatory response,www.WORLDNEUROSURGERY.org 235
Figure 3. Patient 8: Town and lateral projection (A and B), and 3-dimensional angiograms
show a left vertebrobasilar junctional fusiform aneurysm (C and D) and a patent right
posterior communicating artery filling the right middle cerebral artery (A). This patient had
an occlusion of the right internal carotid artery because of head trauma 3 years previously,
and his right vertebral artery V4 segment was aplastic beyond the origin of the posterior
inferior cerebellar artery (not shown here). Nonsubtracted angiogram (E), working
projection anteroposterior view (F) and Dyna CT (G) show the DERIVO embolization
device completely open (first version). The 3-month follow-up angiogram shows the total
closure of the aneurysm and minimal intimal hyperplasia inside the stent (H). However, in
the 9-month follow-up angiograms in the Town (I) and lateral (J) projections, the
hyperplasia has clearly disappeared.
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Table 5. Statistical Data
Studies Number (%)
Technical success 24 (100)
Diffusion MRI
Ischemic lesion þ 5 (20.8)
Ischemic lesion e 19 (79.2)
Morbidity, total
Periprocedural (<24 hours) 1 (4.2)
1e30 days 1 (4.2)
Late (<30 days)
Transient neurologic deficit 2 (8.4)
Mild neurologic deficit 0 (0)
Severe neurologic deficit 0 (0)
Cranial nerve palsy 0 (0)
DED thrombus 1 (4.2)
Permanent neurologic deficit 0 (0)
Mortality, total
Periprocedural (<24 hours) 0 (0)
1e30 days 0 (0)
Late (<30 days) (aneurysm rupture) 1 (4.3)
MRI, magnetic resonance imaging; DED, DERIVO embolization device.
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stent acts as a scaffold for neointimal proliferation and remodeling
of the parent vessel.22
FDs and Morbidity, Mortality, and Closure Rates
The DED has some unique different features that other FDs do
not have. Its blue oxide (blueXide) surface ﬁnishing technology
is a unique polishing technique that makes the device blue and
ensures less friction during delivery through the microcatheter
and during expansion. As we experienced in our study, opening
the device was as easy as opening peripheral braided stents. We
did not encounter any serious opening problems during inser-
tion in our patients. Another difference is that all the nitinol
wires now have opaque platinum cores. These increase the
visibility of the device previously provided solely by the 2
platinum-cored nitinol wires and the proximal and distal opa-
que markers (Figure 4). The thickness of the nitinol strut is 35
mm, and it has a high rate of metal coverage (38%), with a
diameter of 4 mm.24,25
The Pipeline embolization device has 48 cobalt chromium and
platinum strands. The device, initially used for big and giant
aneurysms, has been increasingly used for smaller and less
complex aneurysms.3,10,14,22,27,28 The Silk FD is a braided, nitinol
FD stent including platinum microﬁlaments with low porosity
and a high metal coverage of 35%.22,29,30 The Surpass FD is a
cobalt-chromium alloy device with a low porosity (metal surfaceWORLD NEUROSURGERY 95: 229-240, NOVEMBER 2016area coverage, 30%) and a high mesh density (20e32 pores per
square millimeter). The 2-mm device has 48 wires, the 3- and
4-mm devices have 72 wires, and the 5-mm device has 96
wires to provide a constant high mesh density over the various
diameters of the device.6,19 The FRED is a novel FD stent. It has
a unique dual-layer design composed of a low-porosity inner FD
mesh and a high-porosity outer stent, mainly focusing on the
neck of the aneurysm with its inner part while preserving
the adjacent small vessels with its outer part.5,22 Table 6 shows
the morbidity, mortality, and closure rates of aneurysms
treated with FDs.
In our study, the aneurysms were mostly wide-necked medium-
sized (55.8%) (Table 1); only 32.4% were large and giant. No
patient treated with DEDs was in the acute stage of rupture.
DED deployment in all of our patients was successfully
accomplished. Although 20 (71.4%) of 28 aneurysms in 20
patients were totally closed on the 3-month follow-up angio-
gram, 14 (77.8%) of 18 aneurysms in 9 patients were totally closed
on the ninth month (Figure 3 and Table 3). Our mortality rate was
4.3% (1 patient because of aneurysm rupture), and morbidity was
8.4% (2 patients). These ﬁndings are not so different from the
studies shown in Table 6.
Complications
After aneurysm treatment with FDs, the most feared complica-
tions are aneurysm rupture, intraparenchymal hemorrhage, and
ischemic stroke (mostly because of perforator infarction). Verte-
brobasilar fusiform aneurysms are challenging. The morbi-
mortality rates of those aneurysms treated with FDs are
signiﬁcantly higher than those of the anterior circulation aneu-
rysms treated with FDs.14 The FDs offer the advantage of avoiding
both the manipulation that increases the rupture risk and any coil
insertion that may worsen the preexisting mass effect. In spite of
this, there are many studies and case reports showing that the
post-FD deployment hemorrhagic complications occurred
because of hemodynamic conditions and biochemical changes
after intra-aneurysmal thrombus formation, especially in large and
giant aneurysms.14,18,22 The need for anticoagulant and antith-
rombotic therapy during the procedure and for antithrombotic
therapy after the endovascular procedure result in death in most
patients in the case of iatrogenic or spontaneous bleeding.14
Therefore, many investigators suggest that FD treatment with
coiling should be performed to prevent aneurysmal rupture in
large and giant aneurysms.14
Brinjikji et al.’s meta-analysis of 29 studies14 showed that
subarachnoid hemorrhage (SAH) from delayed aneurysm
rupture occurred in approximately 4% of the patients treated
with FDs, with signiﬁcantly higher rates in patients who had
large and giant aneurysms. Late aneurysm rupture beyond 1
month is relatively rare (2% of the cases). Their study
emphasized that postoperative SAH was a signiﬁcant
complication of FDs. However, it is unknown whether coiling
in addition to FDs would prevent aneurysm rupture. Meta-
analysis showed that the safety of the ﬂow diversion in small
aneurysms was superior to that of large aneurysms, and the latter
has been associated with higher rates of both ischemic infarction
and SAH. There was no speciﬁc aneurysm type associated with
hemorrhage, but they found high association between perforatorwww.WORLDNEUROSURGERY.org 237
Figure 4. Patient 23: Digital subtraction angiographies (A and B) and
maximum intensity projection angiogram (C) show a small, recanalized left
internal carotid artery ophthalmic segment aneurysm coiled 4 months
previously because of subarachnoid hemorrhage. After deployment, the
working projection view (D) and nonsubtracted angiogram (E) show the
new version DERIVO embolization device to be more visible because of
the enhanced opacity provided by the platinum cores of the nitinol wires.
Dyna CT (F) axially cutting the Derivo stent shows that the stent is highly
dense circumferentially.
Table 6. Morbidity, Mortality, and Closure Rates of Aneurysms Treated with Flow Diverters
Study FD
Morbidity
Rate (%)
Mortality
Rate (%)
Complete Occlusion at Follow-up (%)
3 Months 6 Months 9 Months 12 Months 18 Months Overall
Leung et al., 201228 (review) PED 6.3 2.2 82.8
Brinjikji et al., 201314 (meta-analysis) PED and SFD 5 4 76
Arrese et al., 201313
(review and meta-analysis)
PED and SFD 9.9 4.1 76.2
Fischer et al., 201420 PED 5 8 67
Colby et al., 201312 PED 12 3
Murthy et al., 201433 SFD 22.4 4.9 81.8
De Vries et al., 20136 Surpass FD 13.4 0 94
Wakhloo et al., 201519 Surpass FD 12 2.7 75
Kocer et al., 20145 FRED 3 0 67 80
Current study DED 8.4 4.3 71.4 77.8
FD, flow diverter; PED, Pipeline embolization device; SFD, Silk flow diverter, DED, DERIVO embolization device.
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they suggested practitioners be judicious in selecting candidates
for FD therapy, especially for large and posterior circulation
aneurysms.14
Intracerebral hemorrhage is not associated with aneurysmal
rupture. In fact, the intracerebral hemorrhage mechanism is
unknown. Hemorrhagic transformation of ischemic stroke,
hemodynamic alterations, and dual antiplatelet treatment may be
responsible for this complication. Studies have shown that
complication rates ranged from 0% to 10%.14,22,31
Other serious complications of FDs are ischemic stroke and
perforator infarction. To prevent them, proper deployment is
essential because inadequate wall apposition may decrease the ﬂow
with consequent thrombus formation at the interface, followed by
thromboembolic events. Proper deployment and adequate wall
apposition can be achieved by balloon.22 Thromboembolic
complications are also related to the antiplatelet response.32 In
their meta-analysis, Brinjikji et al. reported that the ischemic
stroke rate resulting from thrombus formation along the stent
wall and leading to stent occlusion was 6%. They further reported
that perforator infarction was not uncommon, especially in the
posterior circulation that results from the lack of collateral to the
brain stem perforators. They suggested that the usage of FDs in
the posterior system should be reserved for patients who could
not be treated with other surgical techniques, such as
deconstructive surgery, including parent artery occlusion with
ﬂow reversal.14 Murthy et al.33 reviewed 8 studies with 285
patients and 317 intracranial aneurysms. Ischemic complications
and parent artery occlusion each occurred in 10% of the patients.
The aneurysm rupture rate was 3.5%, whereas the cumulative
mortality was 4.9%.
In our study, the patient we treated with only a DED without
coiling died approximately 6 months later because of aneurysm
rupture. In this patient, intra-aneurysmal thrombus caused a
perianeurysmal biochemical reaction, resulting in the rupture
of the aneurysm (Tables 2 and 3, patient 1). In one patient
(Tables 2 and 3, patient 5), who had a good response to
antiplatelet treatment and for whom a remodeling balloon
was used to provide proper apposition of the stent, a
thromboembolic complication was seen immediately after the
treatment, and the patient was treated with intravenous
tiroﬁban. This patient was discharged without any neurologic
deﬁcit. Another patient had a giant, partially thrombosed, left
posterior communicating artery aneurysm. It was treated with a
DED after coiling, and a remodeling balloon was used for
proper apposition of the stent. The patient was admitted for
stent occlusion with right hemiplegia and loss of consciousness
and was treated and discharged in good condition (Modiﬁed
Rankin Scale score, 1) (Tables 2 and 3, patient 3). This patient
was insensitive to clopidogrel but sensitive to ticlopidine. The
reason of the stent thrombosis was unclear. The vessel was not
dysplastic as well. Nevertheless, the aneurysm had partial
thrombus, and the aneurysm was coiled before insertion of the
DED. The patient may have increased tendency of the thrombus
formation.
In our series, 3 posterior circulation aneurysms in 3 patients
were treated with DEDs without coiling. Although 2 of them were
medium-sized aneurysms, the third was a long vertebrobasilarWORLD NEUROSURGERY 95: 229-240, NOVEMBER 2016fusiform aneurysm compressing the brain stem. This last patient
underwent follow-up and revealed no additional perforator
infarction or neurologic symptoms. In the other 2 patients, a
fusiform and a recanalized saccular aneurysm was completely
closed and reconstructed in the 3- and 9-month follow-up angi-
ographies (Figure 3). In one patient, there was approximately 50%
in-stent stenosis without any neurologic symptoms at the 3-month
follow-up angiography. In another patient, the DED’s ﬁsh-
mouthed formation at the proximal part caused insufﬁcient
opening of the stent. This was relieved with an additional DED
without resulting in in-stent thrombus or distal thromboembolism
(Figure 2 and Tables 2 and 3, patient 4). A remodeling balloon was
applied inside the stent, but proper apposition could not be
obtained.
In our study, the overall complication rate was 16.6%. The
morbidity rate was 8.4% (2 patients), but we did not seen any
permanent or severe neurologic deﬁcits. The mortality rate was
4.3% (1 patient died because of late aneurysm rupture). Our
mortality and morbidity rates were in acceptable ranges compared
with other studies using FDs. Although the morbidity rates were
between 3% and 22.4%, the mortality rates ranged from 0 to 8% in
the literature (Table 6).
Because of the small number of aneurysms treated, we did not
evaluate the relationship of aneurysm rupture to its status as
having been treated either with or without coils in addition to a
FD. Our reason for coiling the aneurysms before FD insertion was
the belief that coiling would decrease the rate of aneurysm
rupture. The patient who died in the sixth month of treatment was
the ﬁrst giant aneurysm patient we had ever treated with a DED or
other FD, but without coiling.
Study Limitations
Several limitations need to be considered. Our study design was
retrospective, single center and unblinded. The follow-up period
was short; the mean aneurysm size was relatively small. The
inhomogeneity of the cases was the major limitation. The patient
population was small as well.CONCLUSIONS
The DED seems effective and safe in the treatment of different
kinds of intracranial aneurysms. However, the treatment of
large and giant aneurysms with FD stents without coiling is
still a problem because of the possibility of aneurysm rupture.
We recommend coiling the aneurysms before or after
implantation of the DED in large and giant aneurysms. This
may provide the early total closure of the aneurysms as well.
Evaluation of aneurysm treatment with FDs requires long-term
studies because the total closure of the aneurysms takes
longer.
The visibility of the DED is high because of the nitinol wires’
opaque platinum cores and the distal and proximal markers. It is
sufﬁcient over compact bones as well.ACKNOWLEDGMENT
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